FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283213065> ?p ?o ?g. }

• W4283213065 abstract "The prognosis of glioblastoma (GBM) remains dismal because therapeutic approaches have limited effectiveness. A new targeted treatment using MEK inhibitors, including trametinib, has been proposed to improve GBM therapy. Trametinib had a promising preclinical effect against several cancers, but its adaptive treatment resistance precluded its clinical translation in GBM. Previously, we have demonstrated that protein arginine methyltransferase 5 (PRMT5) is upregulated in GBM and its inhibition promotes apoptosis and senescence in differentiated and stem-like tumor cells, respectively. We tested whether inhibition of PRMT5 can enhance the efficacy of trametinib against GBM.Patient-derived primary GBM neurospheres (GBMNS) with transient PRMT5 knockdown were treated with trametinib and cell viability, proliferation, cell cycle progression, ELISA, and western blot were analyzed. In vivo, NSG mice were intracranially implanted with PRMT5-intact and -depleted GBMNS, treated with trametinib by daily oral gavage, and observed for tumor progression and mice survival rate.PRMT5 depletion enhanced trametinib-induced cytotoxicity in GBMNS. PRMT5 knockdown significantly decreased trametinib-induced AKT and ERBB3 escape pathways. However, ERBB3 inhibition alone failed to block trametinib-induced AKT activity suggesting that the enhanced antitumor effect imparted by PRMT5 knockdown in trametinib-treated GBMNS resulted from AKT inhibition and not ERBB3 inhibition. In orthotopic murine xenograft models, PRMT5-depletion extended the survival of tumor-bearing mice, and combination with trametinib further increased survival.Combined PRMT5/MEK inhibition synergistically inhibited GBM in animal models and is a promising strategy for GBM therapy." @default.
• W4283213065 created "2022-06-22" @default.
• W4283213065 creator A5001620815 @default.
• W4283213065 creator A5002131638 @default.
• W4283213065 creator A5014807064 @default.
• W4283213065 creator A5026530552 @default.
• W4283213065 creator A5033910333 @default.
• W4283213065 creator A5037448719 @default.
• W4283213065 creator A5039528625 @default.
• W4283213065 creator A5041131555 @default.
• W4283213065 creator A5043407107 @default.
• W4283213065 creator A5047816144 @default.
• W4283213065 creator A5048317276 @default.
• W4283213065 creator A5050741596 @default.
• W4283213065 creator A5057757569 @default.
• W4283213065 creator A5058531555 @default.
• W4283213065 creator A5059574428 @default.
• W4283213065 creator A5061861167 @default.
• W4283213065 creator A5062658027 @default.
• W4283213065 creator A5080479135 @default.
• W4283213065 creator A5083016429 @default.
• W4283213065 creator A5084983983 @default.
• W4283213065 creator A5085640991 @default.
• W4283213065 date "2022-01-01" @default.
• W4283213065 modified "2023-10-18" @default.
• W4283213065 title "Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib" @default.
• W4283213065 cites W1254161066 @default.
• W4283213065 cites W1902577542 @default.
• W4283213065 cites W1999330214 @default.
• W4283213065 cites W2050206485 @default.
• W4283213065 cites W2061760261 @default.
• W4283213065 cites W2091471291 @default.
• W4283213065 cites W2096287682 @default.
• W4283213065 cites W2105437003 @default.
• W4283213065 cites W2109483913 @default.
• W4283213065 cites W2109816625 @default.
• W4283213065 cites W2145348333 @default.
• W4283213065 cites W2160766792 @default.
• W4283213065 cites W2161289668 @default.
• W4283213065 cites W2168805837 @default.
• W4283213065 cites W2429058495 @default.
• W4283213065 cites W2517722622 @default.
• W4283213065 cites W2587625827 @default.
• W4283213065 cites W2766812488 @default.
• W4283213065 cites W2769057657 @default.
• W4283213065 cites W2885459183 @default.
• W4283213065 cites W2897455122 @default.
• W4283213065 cites W2901827204 @default.
• W4283213065 cites W2941500297 @default.
• W4283213065 cites W2944530305 @default.
• W4283213065 cites W2951331822 @default.
• W4283213065 cites W2977603071 @default.
• W4283213065 cites W3100352813 @default.
• W4283213065 cites W3101861808 @default.
• W4283213065 cites W3112784066 @default.
• W4283213065 cites W3186736822 @default.
• W4283213065 doi "https://doi.org/10.1093/noajnl/vdac095" @default.
• W4283213065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35875691" @default.
• W4283213065 hasPublicationYear "2022" @default.
• W4283213065 type Work @default.
• W4283213065 citedByCount "2" @default.
• W4283213065 countsByYear W42832130652022 @default.
• W4283213065 crossrefType "journal-article" @default.
• W4283213065 hasAuthorship W4283213065A5001620815 @default.
• W4283213065 hasAuthorship W4283213065A5002131638 @default.
• W4283213065 hasAuthorship W4283213065A5014807064 @default.
• W4283213065 hasAuthorship W4283213065A5026530552 @default.
• W4283213065 hasAuthorship W4283213065A5033910333 @default.
• W4283213065 hasAuthorship W4283213065A5037448719 @default.
• W4283213065 hasAuthorship W4283213065A5039528625 @default.
• W4283213065 hasAuthorship W4283213065A5041131555 @default.
• W4283213065 hasAuthorship W4283213065A5043407107 @default.
• W4283213065 hasAuthorship W4283213065A5047816144 @default.
• W4283213065 hasAuthorship W4283213065A5048317276 @default.
• W4283213065 hasAuthorship W4283213065A5050741596 @default.
• W4283213065 hasAuthorship W4283213065A5057757569 @default.
• W4283213065 hasAuthorship W4283213065A5058531555 @default.
• W4283213065 hasAuthorship W4283213065A5059574428 @default.
• W4283213065 hasAuthorship W4283213065A5061861167 @default.
• W4283213065 hasAuthorship W4283213065A5062658027 @default.
• W4283213065 hasAuthorship W4283213065A5080479135 @default.
• W4283213065 hasAuthorship W4283213065A5083016429 @default.
• W4283213065 hasAuthorship W4283213065A5084983983 @default.
• W4283213065 hasAuthorship W4283213065A5085640991 @default.
• W4283213065 hasBestOaLocation W42832130651 @default.
• W4283213065 hasConcept C104317684 @default.
• W4283213065 hasConcept C111819275 @default.
• W4283213065 hasConcept C173396325 @default.
• W4283213065 hasConcept C190283241 @default.
• W4283213065 hasConcept C2776131300 @default.
• W4283213065 hasConcept C2777389519 @default.
• W4283213065 hasConcept C2777658100 @default.
• W4283213065 hasConcept C2778227246 @default.
• W4283213065 hasConcept C2778472372 @default.
• W4283213065 hasConcept C2778830669 @default.
• W4283213065 hasConcept C2994587330 @default.
• W4283213065 hasConcept C33288867 @default.
• W4283213065 hasConcept C502942594 @default.
• W4283213065 hasConcept C55493867 @default.
• W4283213065 hasConcept C57074206 @default.

• next